- Home
- MKZR vs RDHL Comparison
MKZR vs RDHL Comparison
Compare MKZR & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKZR | RDHL |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.4M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | MKZR | RDHL |
|---|---|---|
| Price | $2.33 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.3K | ★ 162.7K |
| Earning Date | 05-14-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.71 |
| 52 Week High | $6.99 | $3.31 |
Technical Indicators
Market Signals| Indicator | MKZR | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 37.56 |
| Support Level | $2.25 | $0.76 |
| Resistance Level | $2.52 | $0.89 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 13.79 | 3.57 |
Price Performance
Historical ComparisonAbout MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.